A new study published in Gastroenterology aims to improve the effectiveness of screening and surveillance practices for early cancer detection in Barrett’s esophagus (BE).
FDA Greenlights Imaging Agent to Detect Residual Cancer After Lumpectomy
The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with